MedTrace Logo

EUS vs. MDCT in Pancreatic Malignancy

NCT02115022 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2020-04-28

No results posted yet for this study

Summary

Accurate staging of patients with pancreatic cancer is critical to avoid the expense, morbidity, and mortality related to unnecessary surgery. While several tests are available for assessing such patients, consensus has not been achieved on the optimal approach. As a matter of fact, pancreatic cancer staging is discussed controversially due to conflicting evidence and certainly EUS has lost grounds due to improvements in CT technology. Thus, the role of EUS and EUS-guided FNA varies among treatment centers.

The present study is designed to better define the role of EUS in predicting resectability, as compared to high resolution cross-sectional imaging.

Conditions

  • Resectable Pancreatic Cancer

Sponsors & Collaborators

  • University of Medicine and Pharmacy Craiova

    collaborator OTHER

  • Iuliu Hatieganu University of Medicine and Pharmacy

    collaborator OTHER

  • Institutul Clinic Fundeni

    collaborator OTHER

  • Clinical Hospital Colentina

    lead OTHER

Principal Investigators

  • Mihai Rimbas, MD, PhD · Clinical Hospital Colentina, Carol Davila University of Medicine and Pharmacy

  • Cristian R Baicus, Professor · Clinical Hospital Colentina, Carol Davila University of Medicine and Pharmacy

  • Adrian Saftoiu, Professor · Craiova research Center in Gastroenterology and Hepatology, Craiova University of Medicine and Pharmacy

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2018-01-31
Completion
2018-02-28

Countries

  • Romania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02115022 on ClinicalTrials.gov